LINC02177: A Long Intergenic Non-Protein Coding RNA (G101927009)

Target Name: LINC02177

NCBI ID: G101927009

LINC02177

Other Name(s): long intergenic non-protein coding RNA 2177 | Long intergenic non-protein coding RNA 2177

LINC02177: A Long Intergenic Non-Protein Coding RNA

LINC02177 is a long non-coding RNA (lncRNA) that has been identified in various studies as having important functional roles in various organisms, including humans. This RNA has been shown to play a key role in the regulation of gene expression and has been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, LINC02177 has potential as a drug target or biomarker.

Properties of LINC02177

LINC02177 is a transcribed RNA molecule that is longer than 200 nucleotides. It is characterized by the presence of a stem-loop structure, which is a common feature of many lncRNAs, and by the presence of a variety of non-coding regions, including exons, introns, and untranslated regions.

Expression and function

LINC02177 has been shown to be expressed in various tissues and cells, including the brain, heart, liver, and pancreas. It has also been shown to play important roles in several biological processes, including cell growth, apoptosis, and inflammation.

One of the most significant functions of LINC02177 is its role in cell apoptosis. LINC02177 has been shown to be involved in the regulation of cell death, both in normal development and in response to environmental stressors, such as UV radiation and chemical stress.

In addition to its role in cell apoptosis, LINC02177 has also been shown to play important roles in cell growth and development. It has been shown to be involved in the regulation of cell proliferation and has been shown to play a role in the development and progression of various diseases, including cancer.

Disease associations

The function of LINC02177 as a drug target or biomarker has been the subject of extensive research, and several studies have suggested that it may be involved in the development and progression of several diseases.

One of the most significant associations associated with LINC02177 is its involvement in the development and progression of cancer. Several studies have shown that LINC02177 is expressed in various types of cancer and that it plays a role in the regulation of cell proliferation and apoptosis in these diseases.

Another potential association associated with LINC02177 is its involvement in neurodegenerative diseases. Several studies have shown that LINC02177 is expressed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, LINC02177 has been shown to play a role in the regulation of neurotransmitter synthesis and release, which may be involved in the development of these diseases.

In conclusion, LINC02177 is a long non-coding RNA that has been identified as playing important functional roles in various organisms, including humans. Its function as a drug target or biomarker is currently being explored in several studies, with a focus on its potential involvement in the development and progression of cancer and neurodegenerative diseases. Further research is needed to fully understand the role of LINC02177 in these diseases and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2177

The "LINC02177 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02177 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets